Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. develops and commercializes medicines for hereditary angioedema and other rare diseases. Its commercial product ORLADEYO® (berotralstat) is an oral, once-daily plasma kallikrein inhibitor for HAE, and company updates commonly report ORLADEYO revenue, commercial execution, and financial results.
BioCryst news also covers pipeline and portfolio developments, including investigational plasma kallikrein inhibitor navenibart, rare-disease research programs, licensing arrangements, acquisitions, senior R&D leadership changes, investor conference activity, and Nasdaq inducement equity grants tied to new employee hiring.
BioCryst (Nasdaq: BCRX) will report its first quarter 2026 financial results on Wednesday, May 6, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Investors can access the live call by phone or via a webcast with replay available on the company's investor website.
BioCryst (Nasdaq: BCRX) appointed Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer effective April 6, 2026. Menon joins from Alnylam, where he oversaw global clinical development and helped secure FDA approval of AMVUTTRA.
The company cited the Astria acquisition and the navenibart program moving toward a potential BLA as drivers for sharpening R&D strategy, balancing capital allocation, and preparing for additional rare‑disease launches.
BioCryst (Nasdaq: BCRX) granted inducement equity to 12 newly hired employees on April 1, 2026 under Nasdaq Listing Rule 5635(c)(4). The compensation committee awarded 33,950 stock options and 123,350 RSUs as of the grant date.
The options carry an exercise price of $9.38 (closing price on the grant date), a 10-year term, and both awards vest in four equal annual installments starting on the one-year anniversary, subject to continued service and plan terms.
BioCryst (Nasdaq:BCRX) announced inducement restricted stock unit grants to six newly hired employees covering an aggregate of 65,850 RSUs, granted as of March 2, 2026 under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date and are subject to the company’s Inducement Equity Incentive Plan and individual RSU agreements.
BioCryst (Nasdaq: BCRX) reported full year 2025 results and a business update on Feb 26, 2026. ORLADEYO net revenue was $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO). The company achieved record GAAP and non-GAAP operating profit, completed the Astria acquisition, and received FDA approval for ORLADEYO pellets for ages 2 to <12.
BioCryst maintained 2026 ORLADEYO revenue guidance of $625–$645 million and full year total revenue guidance of $635–$660 million.
BioCryst (Nasdaq: BCRX) will present at the T.D. Cowen 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026 at 9:10 a.m. ET.
According to the company, a live audio webcast and replay will be available in the Investors & Media section of BioCryst's website at www.biocryst.com.
BioCryst (NASDAQ:BCRX) will present nine HAE abstracts at the 2026 AAAAI Annual Meeting (Feb 27–Mar 2, 2026) including six on ORLADEYO (berotralstat) and three on navenibart.
Key data include pediatric interim APeX-P results in children 2 to <12 years and a late‑breaking ALPHA‑SOLAR interim showing sustained attack suppression with navenibart every 3 or 6 months.
BioCryst (Nasdaq: BCRX) will report fourth quarter 2025 financial results on Thursday, February 26, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Live domestic and international dial‑in numbers are provided, and a webcast replay will be available in the investors section of the company website.
BioCryst (Nasdaq: BCRX) announced inducement equity grants for 24 newly hired employees, comprising 251,150 stock options and 368,550 restricted stock units (RSUs) granted as of February 2, 2026, under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $6.63 equal to the closing price on the grant date, vest in four equal annual installments beginning one year from grant, and each option has a 10-year term. Grants are subject to the Inducement Equity Incentive Plan and applicable award agreements.
BioCryst (Nasdaq: BCRX) completed its acquisition of Astria Therapeutics on Jan 23, 2026 for an implied value of approximately $700 million (net of Astria cash). The deal adds navenibart, a Phase 3 long‑acting plasma kallikrein inhibitor with potential every‑three and every‑six month dosing, to BioCryst’s hereditary angioedema (HAE) franchise alongside the oral therapy ORLADEYO. BioCryst financed the cash portion using on‑hand cash and approximately $396.6 million drawn from a Blackstone‑managed financing facility, and issued about 37.3 million shares to Astria equity holders. Leadership additions from Astria join BioCryst’s board and technical ranks to support development and commercialization.